Beer, dolphins and more discoveries that could shed light on Alzheimer’s disease

New Alzheimer's drugs are poised to change the market — and in preclinical arenas, researchers are learning more and more about the disease.

By Michael Gibney • Dec. 22, 2022

Woman of the Week: Exelixis’ Dr. Vicki Goodman

With several blockbuster products under her belt, veteran oncologist and drug developer Dr. Vicki Goodman is looking to further evolve Exelixis’ pipeline to address hard-to-treat cancers.

By Taren Grom • Dec. 14, 2022

The 2023 PharmaVoice Year in Preview

Here’s a look at how industry leaders are navigating the key issues of 2023.

Dec. 12, 2022

With FDA filing on the horizon, Karuna appoints new CEO

Allergan alum Bill Meury will take the helm as current CEO Steve Paul transitions to lead R&D.

By Karissa Waddick • Dec. 9, 2022

For Duchenne-focused Sarepta, gene therapy is the natural next step

The company with three marketed RNA drugs for Duchenne muscular dystrophy is taking the logical leap into gene therapies with a candidate under review at the FDA.

By Michael Gibney • Dec. 8, 2022

10 noteworthy pharma leadership shake-ups this year

From GSK to Roche to Biogen, these were the most impactful executive changes at leading pharma companies in 2022.

By Karissa Waddick • Dec. 7, 2022

Woman of the Week: Simcha Therapeutics’ Beatrice McQueen

From sea sponges to cytokines, the chief operating officer’s career has come full circle as she pursues a new approach to treating cancer via the immune system.

By Taren Grom • Dec. 7, 2022

A historic approval could transform CSL from being ‘the biggest company no one has ever heard of’

The company’s head of R&D on its profile-raising FDA approval of a gene therapy that’s now the world’s most expensive drug. 

By Meagan Parrish • Dec. 6, 2022

Healthcare tech’s biggest busts

The metaverse, blockchain, DCTs and more — here are some of the most recent fails in healthcare tech.

By Taren Grom • Dec. 2, 2022

5 final FDA action dates to watch this year

A potential flurry of regulatory activity could be on the horizon yet this year — and several key drug approvals are at stake.

By Michael Gibney • Dec. 1, 2022

10 of our most popular articles in 2022

Methadone, rock ‘n’ roll, clinical trial overhauls — here’s a look at our most-read stories of the year.

By Meagan Parrish • Nov. 30, 2022

Woman of the Week: Surface Oncology’s Dr. Alison O’Neill

With more than two decades of experience in oncology R&D, Dr. Alison O’Neill is helping Surface unlock the potential of next-gen immunotherapies by targeting the tumor microenvironment.

By Taren Grom • Nov. 30, 2022

One biotech’s approach to science-driven innovation

Why some in the industry say fostering creativity in drug development is all about work structures.

By Karissa Waddick • Nov. 29, 2022

Evommune’s unique method of drug discovery is more than skin deep

The biotech is using human skin squares from plastic surgery to find the best immunological molecules for solving conditions like dermatitis.

By Michael Gibney • Nov. 29, 2022

Avoiding a ‘bad trip’ in psychedelic clinical trials

Psychedelic drug trials pose a number of challenges, but researchers can take these steps to boost patient safety.

By Kelly Bilodeau • Nov. 28, 2022

Woman of the Week: Myriad Genetics’ Nicole Lambert

Empowered by her own cancer journey, Nicole Lambert is using her platform as chief operating officer of the genetic testing powerhouse to change the trajectory of care for millions of women.

By Taren Grom • Nov. 23, 2022

The next era of Greater Boston’s biotech boom

How Boston became the biotech capital of the U.S., and is now preparing for the next era of life sciences growth.  

By Karissa Waddick , Shaun Lucas , Julia Himmel • Nov. 22, 2022

How bacteria-enabled technology for wounds could also help cancer patients

Evelina Vågesjö, co-founder and CEO of the immunotherapy company Ilya Pharma, is working on a new modality to speed wound healing.

By Alexandra Pecci • Nov. 22, 2022

In cancers with very low survival rates, Sellas aims higher

The company hopes its drugs can “take over where other available treatments fail” in multiple types of cancer.

By Kelly Bilodeau • Nov. 21, 2022

Why the biopharma ‘IPO playbook’ changed in 2022

Biopharma IPOs have puttered in 2022, particularly compared to the record-breaking previous year, but they might be set to rebound.

By Michael Gibney • Nov. 21, 2022

Can a formal needs assessment simplify Speaker Bureau compliance?

In the biopharmaceutical industry, phases of innovation and change are often driven by regulatory action.

Nov. 21, 2022

Is AI just hype or a real revolution in pharma? It’s complicated

Artificial intelligence can be a useful tool and will likely augment many processes in biopharma — but it's still early days, and hype is rampant.

By Michael Gibney • Nov. 17, 2022

To explore cancer’s genetic mysteries, researchers turn to ‘MACHETE’

A new CRISPR-based tool could help scientists understand and better treat cancer by revealing the complex genetic mutations that occur.

By Michael Gibney • Nov. 16, 2022

#HLTH: ‘Unicorns are real’ — and here’s how they can navigate a challenging biotech market

Venture capitalists tackle ways companies can stay afloat while the market’s turbulent waters rise.

By Meagan Parrish • Nov. 15, 2022

A ‘bold vision’ to prevent diabetes

Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts. 

By Alexandra Pecci • Nov. 15, 2022